Supplemental Information Disclosure Statement.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicant submits the information listed on the enclosed Form 1449/PTO for consideration in the above-identified application. No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102/103.

This Supplemental Information Disclosure Statement is being filed after the mailing of a final action and before a Notice of Allowance. Accordingly, please charge the necessary fee ($180.00) for the consideration of these references to Account No. 23-2053.

Consideration of the listed references is requested, and return of the enclosed Form 1449/PTO is requested showing the items as being initialed and considered.

The Form 1449/PTO is attached hereto at the **Appendix**.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as *many* sheets as necessary)

Sheet 1 of 1

Complete *if* Known	
Application Number	10/817,058
Filing Date	April 2, 2004
First Named Inventor	John E. Baker
Art Unit	1653
Examiner Name	MAYER, Suzanne Marie
Attorney Docket Number	BA-32448(1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T2
		Flaherty et al., Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men, *Clin. Pharmacol. Ther.* 47(5): 557-564 (1990)	
		Miller et al., Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia, *J. Nathional Cancer Institute* 84(2): 97-103 (1992)	
		Platanias et al., Treatment of Chemotherapy-Induced Anemia with Recombinant Human Erythropoietin in Cancer Patients, *J. Clinical Oncology* 9(11): 2021-2026 (1991)	
		Veng-Pedersen et al., Kinetic Evaluation of Nonlinear Drug Elimination by a Disposition Decomposition Analysis. Application to the Analysis of the Nonlinear Elimination Kinetics of Erythropoietin in Adult Humans, *J. Pharmaceutical Sciences* 84(6): 760-767 (1995)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

AUGUST 5, 2005